TABLE 2.
Gastrointestinal Adverse Events in Clinical Trials of iGlarLixi
| LixiLan-O (23) | LixiLan-L (27) | ||||
|---|---|---|---|---|---|
| iGlarLixi | iGlar | Lixisenatide | iGlarLixi | iGlar | |
| n | 468 | 466 | 233 | 366 | 365 |
| Nausea, n (%) Discontinuation due to nausea |
45 (9.6) 2 (0.4) |
17 (3.6) 0 (0.0) |
56 (24.0) 6 (2.6) |
38 (10.4) 4 (1.1) |
2 (0.5) 0 (0.0) |
| Vomiting, n (%) Discontinuation due to vomiting |
15 (3.2) 2 (0.4) |
7 (1.5) 0 (0.0) |
15 (6.4) 4 (1.7) |
13 (3.6) 0 (0.0) |
2 (0.5) 0 (0.0) |
| Diarrhea, n (%) Discontinuation due to diarrhea |
42 (9.0) 1 (0.2) |
20 (4.3) 0 |
21 (9.0) 2 (0.9) |
16 (4.4) 0 |
10 (2.7) 0 |
iGlar, insulin glargine.